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ittsburgh, Pennsylvania; Stockton, New Jersey; and Westbury, New York
OBJECTIVES The PEECH (Prospective Evaluation of Enhanced External Counterpulsation in Congestive
Heart Failure) study assessed the benefits of enhanced external counterpulsation (EECP) in
the treatment of patients with mild-to-moderate heart failure (HF).
BACKGROUND Enhanced external counterpulsation reduced angina symptoms and extended time to exercise-
induced ischemia in patients with coronary artery disease, angina, and normal left ventricular
function. A small pilot study and registry analysis suggested benefits in patients with HF.
METHODS We randomized 187 subjects with mild-to-moderate symptoms of HF to either EECP and
protocol-defined pharmacologic therapy (PT) or PT alone. Two co-primary end points were
pre-defined: the percentage of subjects with a 60 s or more increase in exercise duration and
the percentage of subjects with at least 1.25 ml/min/kg increase in peak volume of oxygen
uptake (VO2) at 6 months.
RESULTS By the primary intent-to-treat analysis, 35% of subjects in the EECP group and 25% of
control subjects increased exercise time by at least 60 s (p  0.016) at 6 months. However,
there was no between-group difference in peak VO2 changes. New York Heart Association
(NYHA) functional class improved in the active treatment group at 1 week (p  0.01),
3 months (p  0.02), and 6 months (p  0.01). The Minnesota Living with Heart Failure
score improved significantly 1 week (p  0.02) and 3 months after treatment (p  0.01).
CONCLUSIONS In this randomized, single-blinded study, EECP improved exercise tolerance, quality of life,
and NYHA functional classification without an accompanying increase in peak VO2. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.10.079Coll Cardiol 2006;48:1198–205) © 2006 by the American College of Cardiology Foundation
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pnhanced external counterpulsation (EECP) is a noninva-
ive, pneumatic technique that utilizes electrocardiogram-
ated diastolic inflation of a series of lower-extremity cuffs
See page 1206
o effectively increase diastolic and mean intracoronary
ressures as well as coronary flow while reducing systolic
ressure in the central aorta and the coronary artery (1). In
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ccepted October 19, 2005.ddition, EECP improves diastolic filling, decreases left
entricular (LV) end-diastolic pressure, and improves LV
eak filling rate, end-diastolic volume, and time to peak
lling rate (2). This combination of systolic unloading and
ncreased coronary perfusion pressure with external coun-
erpulsation mimics the hemodynamic consequences of
ntra-aortic balloon counterpulsation. Indeed, EECP was
nitially evaluated in the treatment of patients with cardio-
enic shock (3). Repeated administration of EECP has been
hown to have salutary benefits in patients with symptoms
f coronary artery disease and normal LV function despite
ptimal medical therapy (4); patients receiving 35 h of active
ounterpulsation over a 4- to 7-week period demonstrated
educed angina symptoms and extended time to exercise-
nduced ischemia, when compared with a group of patients
andomized to receive sham counterpulsation (4). In addi-
ion, EECP effected a significant improvement in health-
elated quality of life up to 12 months after completion of
reatment (5). Although the specific mechanisms responsi-
le for the beneficial clinical effects of EECP therapy in
atients with symptomatic coronary artery disease remain
nclear, recent studies have demonstrated that a positive
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September 19, 2006:1198–205 Enhanced External Counterpulsation in HFesponse to EECP is associated with enhanced peripheral
ndothelial function (6). In addition, EECP improved stress
yocardial perfusion both at baseline and at maximal
xercise levels (7), reduced plasma levels of brain natriuretic
eptides (2), and improved regional myocardial oxygen
etabolism (8).
In the initial clinical evaluations of EECP, patients were
equired to have normal LV function. However, several
tudies suggested that EECP might also benefit patients
ith LV dysfunction. Approximately 22.3% of patients
nrolled in a voluntary registry of patients undergoing
ECP therapy for treatment of angina pectoris had LV
ysfunction as evidenced by a left ventricular ejection
raction (LVEF) of35% (9). These patients had increased
everity of angina symptoms and higher rates of the com-
osite outcome of death/myocardial infarction/or revascu-
arization as compared with patients with preserved ventric-
lar function. However, patients who did not have an
utcome event had improved anginal status and nitroglyc-
rin use that was comparable to that seen in patients with
ormal LV function. Furthermore, EECP improved exer-
ise capacity and quality of life without adverse conse-
uences in a small group of patients with stable heart failure
HF) who underwent 35 sessions of EECP (10). To address
he efficacy of EECP in patients with symptomatic HF
econdary to systolic dysfunction, we conducted a multi-
enter, controlled clinical trial comparing protocol-defined
harmacologic therapy (PT) (per published guidelines) with
5 1-h sessions of EECP with PT alone.
ETHODS
he PEECH (Prospective Evaluation of Enhanced Exter-
al Counterpulsation in Congestive Heart Failure) trial was
onducted at 29 centers in the U.S. and the U.K. The
omplete protocol has been described elsewhere (11). En-
ollment criteria included New York Heart Association
NYHA) functional class II to III symptoms secondary to
ither ischemic or nonischemic cardiomyopathy, LVEF
35%, and PT consisting of an angiotensin-converting
nzyme inhibitor or an angiotensin-receptor blocker (for at
east 1 month) and a beta-blocker (for at least 3 months)
Abbreviations and Acronyms
EECP  enhanced external counterpulsation
HF  heart failure
LV  left ventricular
LVEF  left ventricular ejection fraction
MLWHF  Minnesota Living with Heart Failure
NYHA  New York Heart Association
PEECH  Prospective Evaluation of Enhanced
External Counterpulsation in Congestive
Heart Failure trial
PT  protocol-defined pharmacologic therapy
VO2  oxygen uptakenless they were not tolerated. Digoxin, diuretics, and other iedications used to treat HF could be given at the inves-
igator’s discretion. After providing written informed con-
ent, eligible patients were randomized in a 1:1 ratio to
reatment with EECP or to continued PT. The study
ersonnel responsible for evaluating study subjects as well as
he steering committee, the end points committee, the
xercise core laboratory, and the sponsor were unaware of
he treatment assignments. Other personnel at the study
enters were not blinded to the randomization and were
harged with providing clinical care and assessing adverse
xperiences. Study files were organized to preserve blinding
f the investigators responsible for evaluating the subjects.
Patients randomly assigned to EECP received 35 1-h
essions over a period of 7 to 8 weeks. Three pneumatic cuffs
ere placed around the lower limbs and buttocks and were
nflated sequentially upward at the onset of diastole, and
eleased rapidly and simultaneously before the onset of
ystole. The protocol-specified applied pressure was 300
m Hg and was reached within 5 min of the initiation of
reatment. Pulse oximetry was monitored continuously dur-
ng the treatment session, and the subject’s clinical status
as re-evaluated if the oxygen saturation dropped by 4%.
atients in both treatment groups were seen in follow-up at
week, 3 months, and 6 months after treatment.
The 2 co-primary end points were the percentage of
ubjects with at least a 60-s increase in exercise duration
rom baseline and the percentage of subjects with at least a
.25-ml/min/kg increase in peak volume of oxygen uptake
VO2) from baseline to 6 months. The exercise test was
tandardized across all centers using a modified Naughton
rotocol and a calibrated treadmill. Peak VO2 was defined as
he oxygen consumption observed at the maximum level of
xercise, as shown by a respiratory exchange ratio (RER)
1, a rating of 14 using the Borg scale of perceived
xertion (15-point, 6 to 20 scale), and identifying the
naerobic threshold, when reached. Raw exercise data were
nalyzed by a core exercise laboratory, blinded to treatment
ssignment and sequence, which provided the results used in
he analysis. Secondary end points included change in
xercise duration, peak VO2, NYHA functional class status,
uality of life, and the occurrence of cardiovascular clinical
utcomes during the treatment phase and the 6-month
ollow-up. The NYHA functional classification was as-
essed and graded by the blinded investigator at each
articipating site. Quality of life was assessed using the
innesota Living with Heart Failure (MLWHF) instru-
ent (12).
Primary analysis was by intent-to-treat, and data from
atients who did not complete the study were analyzed by
arrying forward the last observation. In a secondary anal-
sis, data from patients who withdrew before reaching the
-month end point were censored at the time of the last
valuation. The primary analysis was a logistic regression
hich factors site and baseline. Other variables were ana-
yzed using the Cochran-Mantel-Haenszel test, adjusted for
nvestigator. Continuous variables were analyzed using an
a
i
i
t
e
H
t
d
l
c
m
c
a
s
n
s
a
c
J
s
s
p
i
r
c
f
t
a
f
o
c
s
p
D
R
B
r
T
b
EEC
T
N
M
R
A
E
N
H
B
L
N
E
P
R
V
B
*
f
1200 Feldman et al. JACC Vol. 48, No. 6, 2006
Enhanced External Counterpulsation in HF September 19, 2006:1198–205nalysis of variance, with treatment as a main effect and
nvestigator as a blocking factor. Treatment by investigator
nteraction was tested at the 0.1 level of significance. The
reatment comparison of the 2 co-primary parameters (ex-
rcise duration and peak VO2) was made according to
ochberg’s closed testing procedure (13), with control of
he overall type 1 error at 0.05.
Assumptions with respect to the sample size have been
escribed previously (11). The trial was designed to detect at
east a 60-s increase from baseline in 50% of EECP patients
ompared with 20% of control patients and a 1.25 ml/
in/kg increase in peak VO2 in 50% of EECP patients
ompared with 30% of control patients. Under these design
ssumptions, the study had a 90% power to detect a
tatistically significant difference at the 0.025 level of sig-
ificance and was designed to be positive if there was a
tatistically significant difference in either primary end point
t the 0.025 level or in both end points at the 0.05 level.
The study was managed by an independent coordinating
enter (Anabase International Corporation, Stockton, New
ersey) who performed the statistical data analysis. The
ponsor had no role in the data collection or analysis. A
teering committee oversaw the scientific and clinical as-
ects of the study. Exercise data were conveyed to an
ndependent core laboratory where study quality and data
esults were analyzed. Medical staff at the coordinating
enter were trained to assess the quality of data and tracings
rom the cardiopulmonary exercise tests and, together with
he core laboratory, monitored performance of the testing
nd instructed sites to repeat when necessary to obtain a
ully evaluable test. A data and safety monitoring board
versaw all safety aspects of the study, and an independent
Figure 1. Enrollment and follow-up of patients in the Plinical end-points committee classified adverse events. The
c
vtudy was approved by the institutional review board of each
articipating center and was conducted according to the
eclaration of Helsinki.
ESULTS
etween March 2001 and February 2004, 187 patients were
andomized (93 to EECP and 94 to PT alone) (Fig. 1).
here were no significant differences in baseline variables or
ackground therapy between the 2 treatment groups
H study. EECP  enhanced external counterpulsation.
able 1. Baseline Patient Characteristics*
Characteristics EECP PT Control
umber of patients 93 94
en, n (%) 72 (77.4) 71 (75.5)
ace, Caucasian, n (%) 76 (81.7) 75 (79.8)
ge (mean yrs, SD) 62.4 (11.7) 63.0 (10.4)
tiology, ischemic, n (%) 64 (68.8) 66 (70.2)
YHA, n (%)
Functional class II 60 (64.5) 62 (66.0)
Functional class III 33 (35.5) 32 (34.0)
eart rate, beats/min (SD) 70.7 (11.2) 70.6 (12.0)
lood pressure, mm Hg (SD)
Systolic 116.7 (17.7) 114.8 (18.4)
Diastolic 70.9 (10.2) 70.8 (10.8)
VEF, mean % (SD) 25.9 (6.1) 26.7 (6.5)
umber of patients completing protocol 80 84
xercise duration, s (SE) 610.6 (27.8) 570.9 (26.1)
eak VO2, ml/kg/min (SE) 14.7 (0.4) 14.1 (0.4)
ER (mean, SE) 1.04 (0.01) 1.04 (0.01)
E, l/min 47.9 (1.8) 46.9 (1.6)
org scale score, mean (SE) 16.7 (0.2) 16.6 (0.2)
There was no significant difference between groups.
EECP  enhanced external counterpulsation; LVEF  left ventricular ejection
raction; NYHA  New York Heart Association; PT  protocol-defined pharma-
ologic therapy; RER  respiratory exchange ratio; VE  minute ventilation; VO2 
olume of oxygen uptake;   sitting blood pressure.
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September 19, 2006:1198–205 Enhanced External Counterpulsation in HFTables 1 and 2). Patients were predominantly Caucasian
en with NYHA functional class II HF symptoms who had
mean ejection fraction of 26  6%. Utilization rates of
ackground pharmacologic therapy and average equivalent
oses at baseline demonstrated compliance with guideline-
ecommended therapy (Table 2). Although medication
hanges occurred in individual patients during the trial,
here were no significant differences between treatment
roups, and average equivalent doses remained the same at
ach time point. In particular, there were no differences in
iuretic dosing during the study (data not shown).
Exercise duration increased by 60 s or more in 35.4% of
atients in the group assigned to EECP as compared with
5.3% of patients in the pharmacologic treatment group at
he 6-month follow-up visit (p  0.016) (Fig. 2). By
ontrast, the percentage of subjects who demonstrated an
igure 2. The percentage of patients who had at least a 60-s increase fr
able 2. Protocol-Defined Pharmacologic Therapy Utilization
ate and Dose Equivalents at Baseline*
HF Treatment EECP PT Control
CE inhibitors, n (%) 70 (75.3) 73 (77.7)
nalapril daily dose equivalent (mg)
Mean (SD) 11.8 (10.1) 13.5 (9.9)
Median 10 10
RBs, n (%) 18 (19.4) 18 (19.1)
osartan daily dose equivalent (mg)
Mean (SD) 63.2 (42.0) 60.5 (38.5)
Median 50 50
eta-blockers, n (%) 79 (84.9) 81 (86.2)
arvedilol daily dose equivalent (mg)
Mean (SD) 39.4 (29.7) 39.7 (30.1)
Median 25 25
There were no significant differences between groups.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker;
F  heart failure. Other abbreviations as in Table 1.1.25 ml/kg/min from baseline at 6 months after treatment (co-primary end
xygen uptake. Solid bar  enhanced external counterpulsation; open bar  cncrease in peak VO2 of 1.25 ml/kg/min did not differ
etween the 2 treatment groups (22.8% vs. 24.1%) at the
ame visit. EECP treatment was also associated with a
ignificant increase in exercise time at 1 week, 3 months,
nd 6 months when compared with those patients receiving
harmacologic therapy alone (Table 3). While there was a
rend at 1 week and 3 months, EECP did not effect a
ignificant increase from baseline in peak VO2 at any time
oint. Similarly, there was no change in ventilatory equiv-
lent for carbon dioxide (Ve/VCO2) at any time point (data
ot presented). There were no between-group differences in
ER or Borg score (overall median 17) at baseline or any
ollow-up time points. However, there were differences in
entilatory response at 1 week and 3 months after
reatment (Table 3). The benefit of EECP on exercise
uration was also evident when data from patients who
ithdrew from the study were censored at the time of the
ast visit (data on file). Analysis of site interaction on the
rimary end points yielded no statistically significant differ-
nces. In addition, evaluation of the primary end point at
hose sites with larger enrollments demonstrated results that
ere consistent with the overall study results. Consistent
ith an improvement in exercise time, EECP also effected
significant improvement in NYHA functional class and
uality of life. The percentage of patients who demonstrated
n improvement in NYHA symptoms was significantly
arger in the group receiving EECP than in patients
eceiving pharmacologic therapy alone at 1 week, 3 months,
nd 6 months after therapy (Fig. 3). Similarly, EECP
ffected a statistically significant improvement in quality of
ife as measured by the MLWHF questionnaire at 1 week
nd 3 months after completion of EECP therapy, but not at
aseline in exercise duration and the percentage of patients with at leastom b
points; intent-to-treat analysis, last observation carried forward). VO2 
ontrol subjects.
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Enhanced External Counterpulsation in HF September 19, 2006:1198–205months after treatment (Fig. 3). Analysis of changes in
mprovement in NYHA functional classification and quality
f life did not change when data from patients who
ithdrew from the study were censored at the time of
ithdrawal (data on file).
We assessed whether differences existed in response to
ECP therapy in patients with HF secondary to either
schemic or nonischemic dilated cardiomyopathy. Albeit, in
relatively small sample size, subgroup analysis based on
tiology of disease demonstrated benefit in patients with
schemic cardiomyopathy, while this difference was not seen
n the small number of patients with nonischemic disease
Table 3). Similarly, when assessing the effects of EECP on
YHA functional classification, there was a greater propor-
ion of patients showing improvement in the EECP group
hen compared with those receiving pharmacologic therapy
lone at all time points in the group with ischemic disease
1 week: 37.0% EECP vs. 12.7%, p  0.004: 3 months:
4.5% vs. 12.3%, p  0.025; 6 months: 36.4% vs. 15.5%,
 0.026). In addition, quality of life was significantly
mproved in the ischemic group at 3 months of follow-up
6.5  3.2 EECP vs. 1.5  2.1 PT, p  0.046) but not
t any time point in patients receiving EECP who had a
able 3. Mean Change From Baseline in Exercise Duration and
EECP
No. Mean Chan
1-Week
hange exercise duration (s) 77 26.4  1
Ischemic 53 24.6  1
Nonischemic 24 30.2  1
hange in peak VO2 (ml/kg/min) 77 0.1  0
Ischemic 53 0.2  0
Nonischemic 24 0.2  0
hange in RER 77 0.01  0
hange in VE (l/min) 77 0.4  1
3-Month
hange exercise duration (s) 78 34.5  1
Ischemic 54 34.2  1
Nonischemic 24 35.4  2
hange in peak VO2 (ml/kg/min) 78 0.2  0
Ischemic 54 0.0  0
Nonischemic 24 0.6  0
hange in RER 78 0.00  0
hange in VE (l/min) 78 0.5  0
6-Month
hange exercise duration (s) 79 24.7  1
Ischemic 54 20.6  1
Nonischemic 25 33.5  2
hange in peak VO2 (ml/kg/min) 79 0.3  0
Ischemic 54 0.4  0
Nonischemic 25 0.3  0
hange in RER 79 0.00  0
hange in VE (l/min) 79 0.8  1
ntent-to-treat analysis, last observation carried forward. *p value was obtained from
f significant, and covariate baseline value.
Abbreviations as in Table 1.onischemic etiology. However, no significant differences in ihe parameters of exercise duration, peak VO2, functional
lassification, or quality of life were detected within treat-
ent assignment subgroups.
We also performed a post-hoc analysis to assess whether
ny predictors of response to EECP were identifiable.
nalysis of co-primary end point responder rates based
pon age, gender, race, etiology, NYHA functional classi-
cation, LVEF, height, weight, and body mass index above
ersus below median values were performed. No statistically
ignificant differences were found between responders and
onresponders in the EECP group, while younger age (p 
.004), female gender (p  0.006), higher LVEF (p 
.027), and less weight (p  0.027) predicted response in
he control group.
Fewer patients completed the study in the active treat-
ent group (76%) than in the control group (86%), largely
ue to more patients in the EECP group discontinuing due
o an adverse experience (11.8% EECP vs. 3.2% PT).
dverse events that occurred in relation to the application of
ECP therapy resulting in discontinuation included sciatica
1 patient), leg pain (1 patient), and arrhythmia, which
nterfered with application of the therapy (2 patients). One
ther EECP subject suffered a non–Q-wave myocardial
VO2
PT Control
SE No. Mean Change  SE p Value*
ow-Up
78 5.5  11.7 0.010
54 16.7  14.2 0.007
24 19.9  20.3 0.836
78 0.4  0.3 0.071
54 0.7  0.4 0.008
24 0.4  0.5 0.987
78 0.00  0.01 0.363
78 2.1  1.0 0.011
low-Up
82 7.0  12.7 0.014
57 17.3  13.1 0.017
25 16.7  28.9 0.741
82 0.4  0.3 0.119
57 0.4  0.3 0.122
25 0.2  0.8 0.437
82 0.01  0.01 0.252
82 2.3  1.2 0.010
low-Up
83 9.9  13.2 0.013
57 25.8  13.9 0.010
26 24.7  28.3 0.724
83 0.6  0.3 0.315
57 0.9  0.3 0.115
26 0.2  0.6 0.935
83 0.00  0.01 0.161
83 2.4  1.1 0.094
is of covariance with main effects etiology, investigator, and etiology by investigator,Peak
ge 
Foll
2.2
5.7
8.3
.3
.4
.5
.01
.0
Fol
3.9
7.2
3.8
.3
.4
.5
.01
.9
Fol
5.2
8.5
6.8
.3
.3
.5
.01
.0
analysnfarction during the treatment period not attributable to
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September 19, 2006:1198–205 Enhanced External Counterpulsation in HFhe therapy. During the follow-up period, 6 additional
ubjects from the EECP group discontinued due to wors-
ning HF (4 patients), biventricular pacemaker implanta-
ion (1 patient), and worsening lung cancer (1 patient).
dverse events in the control group leading to discontinu-
tion included 2 deaths during the treatment period and 1
nstance of atrioventricular block during the follow-up
eriod.
However, the number of pre-defined clinical events that
ccurred during the trial was not different between the
roup of patients who received EECP and those in the
ontrol group (Table 4). In addition, the number of adverse
vents and the number of serious adverse events were equal
n the 2 treatment groups. The number of subjects random-
zed to EECP therapy that experienced any adverse event or
serious adverse event was nearly identical to that in the
harmacologic therapy group. Two patients had serious
dverse events that the site investigator attributed to EECP
uring the treatment period: 1 patient experienced worsen-
ng HF while a second patient developed a pulmonary
mbolism. During the post-treatment period, an additional
atient developed a deep venous thrombosis that was
ttributed by the investigator to EECP. A temporary
ecrease in oxygen saturation observed by pulse oximetry
ccurred in 11 (12.4%) subjects in 30 (1%) of 2,859 EECP
herapy sessions administered during the trial. Except for 1
ase of oxygen desaturation followed by a worsening of HF
fter the treatment session, all other episodes were reversed
y a protocol-mandated brief interruption of the treatment
ession and improved breathing.
ISCUSSION
he results of the PEECH trial demonstrate that 35 1-h
igure 3. Percentage of patients who improved in their New York Heart
core (right) at 1 week, 3 months, and 6 months compared with baselineessions of EECP over a period of 7 weeks benefited gatients with mild-to-moderate HF and systolic LV dys-
unction who were receiving PT. Enhanced external coun-
erpulsation effected a statistically significant increase (p 
.016) in the percentage of patients exceeding a 60-s
mprovement in exercise time, making this a positive trial
ased on the predefined statistical criteria for the primary
nd-point analysis. However, it must be noted that EECP
id not alter the percentage of patients demonstrating an
ncrease of 1.25 ml/kg/min in peak VO2. Consistent with
he improvement in the percentage of patients exceeding a
0-s improvement in exercise time, patients receiving active
herapy also demonstrated a modest increase in exercise
ime when assessed as increase from baseline and an
mprovement in NYHA HF symptoms. These benefits of
ECP were demonstrable after completion of EECP
herapy as well as for up to 6 months. The active
reatment group also reported an improvement in quality
f life that was sustained for 3 but not 6 months. Peak
O2, when measured as change from baseline, showed a
rend towards benefit in the active treatment group at 1
eek and 3 months, but there was not a statistically
ignificant difference between the 2 study groups.
Overall, the use of EECP was well tolerated. Two
atients had serious adverse events during the treatment
eriod. One patient had a pulmonary embolism. Because
ECP “milks” the vasculature of the lower extremities, this
s a recognized side effect and points out that patients at risk
or deep venous thrombosis should be carefully evaluated
efore undergoing EECP therapy and monitored closely
uring the course of treatment. A second patient experi-
nced worsening HF. This may have been secondary to
ncreased venous load during EECP therapy. A larger
umber of patients withdrew from the study in the EECP
iation (NYHA) functional class (left) and mean change in quality-of-life
P  enhanced external counterpulsation.roup due to adverse events, most of which were associated
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Enhanced External Counterpulsation in HF September 19, 2006:1198–205ith the application of EECP. Some patients experienced
iscomfort that obviated their continued participation.
owever, it is noteworthy that the number of adverse events
r serious adverse events did not differ between the 2 study
roups over the course of the trial.
The design of the PEECH trial was influenced by
oncerns that “sham” EECP altered vascular hemodynam-
cs. Indeed, even low-pressure EECP is associated with a
arked increase in right ventricular filling, while not asso-
iated with a decrease in peripheral vascular resistance (A.D.
ichael, unpublished data, November 2003). Thus, inves-
igators were concerned that “sham” EECP might actually
ncrease the incidence of HF because increased right ven-
ricular loading would not be offset by decreased peripheral
ascular resistance. Furthermore, it was observed in the
UST EECP (Multicenter Study of Enhanced External
ounterpulsation) trial that changes in exercise time were
een in patients treated with “sham” EECP (4). Thus, we
elieved that EECP could only be evaluated using an
nblinded control group. To obviate bias on the part of
nvestigators, each study site had 2 separate teams, an
nvestigative team and a patient care team, and both patients
nd coordinators were educated regarding the need for
onfidentiality between the members of these 2 groups.
urthermore, study coordinators who came into contact
ith the patient on a daily basis during active treatment
ere instructed not to address clinical issues with their
atients. Thus, assiduous efforts were undertaken to sepa-
ate the study team from the clinical care team, consistent
ith the single-blind trial design. That there was consis-
ency across all study centers with respect to protocol
andates was evidenced by the fact that there were no
ntercenter differences in study results. However, this design
able 4. SAEs*
EECP PT Control
ubjects with SAEs, n (%) 27 (30.3) 26 (29.5)
ccurring during treatment period
Subjects with SAEs, n (%) 7 (7.9) 8 (9.1)
SAEs related to treatment
WHF 1
Pulmonary embolism 1
ccurring during follow-up
Subjects with SAEs, n (%) 21 (23.6) 23 (26.1)
SAEs related to treatment
WHF 1
Deep venous thrombosis 1
re-defined clinical events 89 88
WHF with IV, n (%) 8 (9.0) 12 (13.6)
WHF with no IV, n (%) 8 (1.1) 4 (2.3)
ACS, n (%) 1 (1.1) 0 (0.0)
MI, n (%) 4 (4.5) 0 (0.0)
Cardiovascular death, n (%) 0 (0.0) 2 (2.3)
There were no significant differences between groups.
ACS  acute coronary syndrome, non-MI; EECP  enhanced external counter-
ulsation; MI  myocardial infarction; PT  protocol-defined pharmacologic
herapy; SAEs serious adverse events; WHF worsening heart failure; WHF with
V  worsening heart failure, hospitalized, requiring IV therapy; WHF with no IV
orsening heart failure not requiring IV therapy.ay not mitigate against the possibility that daily visits forperiod of 7 weeks might have benefited patients in the
ctive treatment group.
The finding that EECP increased exercise time but did
ot effect a statistically significant change in peak VO2 raises
n interesting conundrum. One possible explanation for this
isparity is that the beneficial effects of EECP in the
EECH study were attributable to a “placebo” effect in the
ctive treatment group in view of the fact that these patients
ere not blinded to their treatment assignment. The finding
hat significant improvements in quality-of-life scores de-
reased over time in the EECP group is also suggestive of a
lacebo effect. Alternatively, we may have underpowered the
rial for a change in peak VO2 as there was a trend towards
n increase in peak VO2 at both 1 week and 3 months,
hough these trends did not reach statistical significance.
etra et al. (14) recently found that treatment with carve-
ilol effected a significant improvement in exercise duration
ithout an accompanying change in peak VO2 in a small
roup of optimally medicated patients with predominantly
YHA functional class II to III HF symptoms. It is
nlikely that our failure to see a change in peak VO2 was due
o our selection of thresholds as the thresholds of 60 s
mprovement in exercise duration and 1.25 ml/kg/min
mprovement in peak VO2 were significantly greater than
hat had been observed in control groups of major HF
reatment trials reported before the planning phase of this
rial.
In summary, EECP improved exercise tolerance and HF
ymptoms in patients with NYHA functional class II and
II HF who were receiving PT but did not improve peak
O2. Because patients were not blinded to therapy, these
enefits of EECP may be attributable to a “placebo” effect.
owever, the usefulness of EECP by physicians must be
ndividualized based on their assessment of the totality of
ECP data. Further studies may help elucidate both the
echanism of action and the overall effects of EECP
herapy.
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